BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38721515)

  • 1. Effectiveness and safety of early lens extraction during par plana vitrectomy for proliferative diabetes retinopathy with mild cataract: a randomized clinical trial.
    Feng WB; Zheng L; Li YQ; Li YH; Zhang GM; Wang X; Liu BQ; Jin L; Huang YN; Yang YF; Chen ZD; Ma DH; Chen QS; Qin CJ; Feng BM; Yang ZM; Huang X; Yang CJ; Liu SH; Wu MX
    Int J Ophthalmol; 2024; 17(3):528-536. PubMed ID: 38721515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pars plana vitrectomy with internal limiting membrane flap versus pars plana vitrectomy with conventional internal limiting membrane peeling for large macular hole.
    Ghoraba H; Rittiphairoj T; Akhavanrezayat A; Karaca I; Matsumiya W; Pham B; Mishra K; Yasar C; Mobasserian A; Abdelkarem AA; Nguyen QD
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD015031. PubMed ID: 37548231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pars plana vitrectomy and combined pars plana vitrectomy with phacoemulsification for proliferative diabetic retinopathy: A retrospective study about 120 eyes.
    Ben Addou Idrissi S; Bengebara O; Filali Sadouk M; Himmich M; Lahlou L; El Ouazzani Taybi H; Moutei H; Bennis A; Chraibi F; Abdellaoui M; Benatiya Andaloussi I
    Indian J Ophthalmol; 2024 Feb; 72(Suppl 2):S287-S292. PubMed ID: 38271425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pars plana vitrectomy, phacoemulsification and intraocular lens implantation for the management of cataract and proliferative diabetic retinopathy: comparison of a combined versus two-step surgical approach].
    Rivas-Aguiño P; García-Amaris RA; Berrocal MH; Sánchez JG; Rivas A; Arévalo JF
    Arch Soc Esp Oftalmol; 2009 Jan; 84(1):31-8. PubMed ID: 19173136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of visual outcome after pars plana vitrectomy secondary to proliferative diabetic retinopathy.
    Nisic F; Gadzo AP; Fajkic A; Nisic A; Miokovic AP; Damjanovic G; Begic E; Beslic N; Lepara O
    Rom J Ophthalmol; 2023; 67(3):283-288. PubMed ID: 37876512
    [No Abstract]   [Full Text] [Related]  

  • 6. Visual outcomes from pars plana vitrectomy versus combined pars plana vitrectomy, phacoemulsification, and intraocular lens implantation in patients with diabetes.
    Silva PS; Diala PA; Hamam RN; Arrigg PG; Shah ST; Murtha TL; Schlossman DK; Cavallerano JD; Sun JK; Aiello LP
    Retina; 2014 Oct; 34(10):1960-8. PubMed ID: 24830822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis value of Chinese Ocular Fundus Diseases Society classification for proliferative diabetic retinopathy on postoperative visual acuity after pars plana vitrectomy in type 2 diabetes.
    Lin TZ; Kong Y; Shi C; Eric Pazo E; Dai GZ; Wu XW; Xu L; Shen LJ
    Int J Ophthalmol; 2022; 15(10):1627-1633. PubMed ID: 36262848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endodiathermy plus photocoagulation as treatment of sclerotomy site vascularization secondary to pars plana vitrectomy for proliferative diabetic retinopathy.
    Nadal J; Carreras E; Canut MI
    Retina; 2012 Jul; 32(7):1310-5. PubMed ID: 22466471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pars plana lensectomy, pars plana vitrectomy, and silicone oil tamponade as initial management of cataract and combined traction/rhegmatogenous retinal detachment involving the macula associated with severe proliferative diabetic retinopathy.
    Douglas MJ; Scott IU; Flynn HW
    Ophthalmic Surg Lasers Imaging; 2003; 34(4):270-8. PubMed ID: 12875454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Pars Plana Vitrectomy With or Without Cataract Surgery in Patients with Diabetes: A Systematic Review and Meta-Analysis.
    Xiao K; Dong YC; Xiao XG; Liang SZ; Wang J; Qian C; Wan GM
    Diabetes Ther; 2019 Oct; 10(5):1859-1868. PubMed ID: 31347099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of Diabetes Status on the Rate of Cataract Surgery Following Pars Plana Vitrectomy.
    Faramawi MF; Delhey LM; Chancellor JR; Sallam AB
    Ophthalmol Retina; 2020 May; 4(5):486-493. PubMed ID: 31786136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation.
    Castillo J; Aleman I; Rush SW; Rush RB
    Am J Ophthalmol; 2017 Nov; 183():1-10. PubMed ID: 28860046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical outcomes of 23-gauge transconjunctival pars plana vitrectomy combined with lensectomy for glaucomatous eyes with extremely shallow anterior chamber and cataract.
    Zhang Z; Zhang S; Jiang X; Qiu S; Wei Y
    BMC Ophthalmol; 2016 Jan; 16():2. PubMed ID: 26728361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INCIDENCE OF LENS TOUCH DURING PARS PLANA VITRECTOMY AND OUTCOMES FROM SUBSEQUENT CATARACT SURGERY.
    Elhousseini Z; Lee E; Williamson TH
    Retina; 2016 Apr; 36(4):825-9. PubMed ID: 27018809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined surgery and sequential surgery comprising phacoemulsification, pars plana vitrectomy, and intraocular lens implantation: comparison of clinical outcomes.
    Chung TY; Chung H; Lee JH
    J Cataract Refract Surg; 2002 Nov; 28(11):2001-5. PubMed ID: 12457677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined phaco-vitrectomy provides lower costs and greater area under the curve vision gains than sequential vitrectomy and phacoemulsification.
    Port AD; Nolan JG; Siegel NH; Chen X; Ness SD; Subramanian ML
    Graefes Arch Clin Exp Ophthalmol; 2021 Jan; 259(1):45-52. PubMed ID: 32813107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence and risk factors of neovascular glaucoma secondary to proliferative diabetic retinopathy after vitrectomy.
    Sun D; Lin Y; Zeng R; Yang Z; Deng X; Lan Y
    Eur J Ophthalmol; 2021 Nov; 31(6):3057-3067. PubMed ID: 33334171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Smith JM; Steel DH
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Antoszyk AN; Glassman AR; Beaulieu WT; Jampol LM; Jhaveri CD; Punjabi OS; Salehi-Had H; Wells JA; Maguire MG; Stockdale CR; Martin DF; Sun JK;
    JAMA; 2020 Dec; 324(23):2383-2395. PubMed ID: 33320223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical strategy and outcome in patients with bilateral proliferative diabetic retinopathy.
    Jiang JH; Wu RH; Ren MX; Lin K; Lin W; Hu XT; Chen F; Zhao ZQ; Ge LN; Lin Z
    Int Ophthalmol; 2023 Dec; 43(12):4921-4931. PubMed ID: 37837486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.